HILDEN and ROSTOCK, Germany and GERMANTOWN, Maryland,
QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) and CENTOGENE AG today announced a collaboration and co-marketing agreement to provide customers more complete Sample to Insight research and clinical testing solutions in rare genetic diseases. CENTOGENE is a leading rare disease company providing insights into the complex interaction between genetics, biochemistry and clinical phenotypes of patients with hereditary disorders. More than 4,000 known genetic disorders are estimated to affect roughly 1 in 10 individuals.
Click here for the full press release https://corporate.qiagen.com/newsroom/press-releases/2017/2017-10-09-Centogene?sc_lang=en
Contacts: QIAGEN Public Relations Dr. Thomas Theuringer e-mail: pr@QIAGEN.com +49-2103-29-11826
Investor Relations John Gilardi e-mail: ir@QIAGEN.com +49-2103-29-11711
CENTOGENE CEOīs office Doreen Niemann e-mail: firstname.lastname@example.org +49-381-203-652-181
SOURCE Qiagen N.V.
Subscribe to our Free Newsletters!
Fallopian tube cancer is a form of gynecologic cancer arising in the fallopian tubes, which are ...
Cushing syndrome is a collection of symptoms caused due to excessive amount of cortisol in the body ...
CAR T-cell therapy is a type of gene therapy where the patient's T-lymphocytes are genetically ...View All